Free Trial
NASDAQ:SRZN

Surrozen Q3 2026 Earnings Results & Report

Surrozen logo
$32.79 +0.79 (+2.48%)
As of 03:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Surrozen missed analyst expectations on both earnings and revenue in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$11.02 versus the -$1.10 consensus estimate, while revenue of $450 thousand fell short of the $475 thousand estimate by $25.00 thousand.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Surrozen EPS Results

Actual EPS
-$11.02
Consensus EPS
-$1.10
Beat/Miss
Missed by -$9.92
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Surrozen Revenue Results

Actual Revenue
$450 thousand
Expected Revenue
$475 thousand
Beat/Miss
Missed by -$25.00 thousand
YoY Revenue Growth
N/A

Surrozen Q3 2026 Earnings FAQ

Surrozen (NASDAQ:SRZN) reported earnings of -$11.02 per share for Q3 2026, missing the consensus estimate of -$1.10. The report was announced on Monday, November 9, 2026.

Surrozen reported revenue of $450 thousand for Q3 2026, against a consensus estimate of $475 thousand.

Surrozen Earnings Headlines

Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
Surrozen (SRZN) Expected to Post Quarterly Earnings on Friday
See More Surrozen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Surrozen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Surrozen and other key companies, straight to your email.

About Surrozen

Surrozen (NASDAQ:SRZN) is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation.

The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues. Its development programs have focused on potential treatments for diseases involving the liver, gastrointestinal system and other tissues where impaired regeneration contributes to disease.

Surrozen’s pipeline has included SZN-043, an investigational Wnt pathway agonist being developed for liver-related conditions, and SZN-1326, an investigational program aimed at gastrointestinal diseases such as ulcerative colitis. The company’s programs remain subject to clinical testing and regulatory review, and their safety and effectiveness have not been established.

View Surrozen Profile